Amgen names new member of board of directors

Amgen has announced the appointment of Gladstone Institutes president Dr Sanders Williams to its board of directors.

Dr Williams, Gladstone's current Robert and Linda Mahley Distinguished Professor, will serve on the corporate responsibility and compliance committee and governance and nominating committee in his new role at Amgen.

He has been with Gladstone, a not-for-profit biomedical research enterprise, since 2010, having previously held academic roles at a number of a high-profile US institutions. He is also a former director of the pharmaceutical company Bristol-Myers Squibb.

Following his appointment, the company's board now consists of 13 members, of whom 12 are independent.

Robert Bradway, chairman and chief executive officer of Amgen, said: "Dr Williams' deep and distinguished experience in academic medicine and his direct experience in our industry will both be of immense value as we extend Amgen's therapeutic and geographic reach to serve more patients."

This follows the appointment of Elliot Levy as the company's new senior vice-president for global development last month.